186 related articles for article (PubMed ID: 34708886)
1. Colchicine, COVID-19 and hematological parameters: A meta-analysis.
Sarwar M; Ali Z; Fatima M; Sarfraz Z; Sarfraz A; Cherrez-Ojeda I
J Clin Lab Anal; 2021 Dec; 35(12):e24057. PubMed ID: 34708886
[TBL] [Abstract][Full Text] [Related]
2. Anakinra treatment efficacy in reduction of inflammatory biomarkers in COVID-19 patients: A meta-analysis.
Naveed Z; Sarwar M; Ali Z; Saeed D; Choudhry K; Sarfraz A; Sarfraz Z; Felix M; Cherrez-Ojeda I
J Clin Lab Anal; 2022 Jun; 36(6):e24434. PubMed ID: 35435272
[TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
4. CRP, SAA, LDH, and DD predict poor prognosis of coronavirus disease (COVID-19): a meta-analysis from 7739 patients.
Wang L; Yang LM; Pei SF; Chong YZ; Guo Y; Gao XL; Tang QY; Li Y; Feng FM
Scand J Clin Lab Invest; 2021 Dec; 81(8):679-686. PubMed ID: 34762008
[TBL] [Abstract][Full Text] [Related]
5. Laboratory features of severe vs. non-severe COVID-19 patients in Asian populations: a systematic review and meta-analysis.
Ghahramani S; Tabrizi R; Lankarani KB; Kashani SMA; Rezaei S; Zeidi N; Akbari M; Heydari ST; Akbari H; Nowrouzi-Sohrabi P; Ahmadizar F
Eur J Med Res; 2020 Aug; 25(1):30. PubMed ID: 32746929
[TBL] [Abstract][Full Text] [Related]
6. Inflammatory and hematologic markers as predictors of severe outcomes in COVID-19 infection: A systematic review and meta-analysis.
Hariyanto TI; Japar KV; Kwenandar F; Damay V; Siregar JI; Lugito NPH; Tjiang MM; Kurniawan A
Am J Emerg Med; 2021 Mar; 41():110-119. PubMed ID: 33418211
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of colchicine in COVID-19 patients: A systematic review and meta-analysis of randomized control trials.
Yasmin F; Najeeb H; Moeed A; Hassan W; Khatri M; Asghar MS; Naveed AK; Ullah W; Surani S
PLoS One; 2022; 17(4):e0266245. PubMed ID: 35381033
[TBL] [Abstract][Full Text] [Related]
8. The inflammatory markers of multisystem inflammatory syndrome in children (MIS-C) and adolescents associated with COVID-19: A meta-analysis.
Zhao Y; Yin L; Patel J; Tang L; Huang Y
J Med Virol; 2021 Jul; 93(7):4358-4369. PubMed ID: 33739452
[TBL] [Abstract][Full Text] [Related]
9. Mortality in Patients of COVID-19 Infection: Biochemical Markers and its Cut-off Values for Predicting Outcome.
Yousaf MN; Sarwar S; Tarique S; Ahmed M; Tahir H
J Coll Physicians Surg Pak; 2022 Jan; 32(1):37-41. PubMed ID: 34983145
[TBL] [Abstract][Full Text] [Related]
10. Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial.
Deftereos SG; Giannopoulos G; Vrachatis DA; Siasos GD; Giotaki SG; Gargalianos P; Metallidis S; Sianos G; Baltagiannis S; Panagopoulos P; Dolianitis K; Randou E; Syrigos K; Kotanidou A; Koulouris NG; Milionis H; Sipsas N; Gogos C; Tsoukalas G; Olympios CD; Tsagalou E; Migdalis I; Gerakari S; Angelidis C; Alexopoulos D; Davlouros P; Hahalis G; Kanonidis I; Katritsis D; Kolettis T; Manolis AS; Michalis L; Naka KK; Pyrgakis VN; Toutouzas KP; Triposkiadis F; Tsioufis K; Vavouranakis E; Martinèz-Dolz L; Reimers B; Stefanini GG; Cleman M; Goudevenos J; Tsiodras S; Tousoulis D; Iliodromitis E; Mehran R; Dangas G; Stefanadis C;
JAMA Netw Open; 2020 Jun; 3(6):e2013136. PubMed ID: 32579195
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of colchicine in the management of coronavirus disease 2019: A protocol for systematic review and meta-analysis.
Elshafei MN; Khalil A; El-Bardissy A; Danjuma M; Ahmed MB; Mohamed MFH
Medicine (Baltimore); 2020 Sep; 99(36):e21911. PubMed ID: 32899023
[TBL] [Abstract][Full Text] [Related]
12. Can we still consider treatment with colchicine effective in SARS-COV-2 infection? Systematic review, meta-analysis, and trial sequential analysis.
De-Miguel-Balsa E; Estevan-Ortega R; Sempere-Selva MT; Latour-Pérez J; Baeza-Román A; Moya-Martinez A; Ramos-Rincon JM
Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7151-7161. PubMed ID: 34859881
[TBL] [Abstract][Full Text] [Related]
13. Association of serum C-reactive protein (CRP) and D-dimer concentration on the severity of COVID-19 cases with or without diabetes: a systematic review and meta-analysis.
Debi H; Itu ZT; Amin MT; Hussain F; Hossain MS
Expert Rev Endocrinol Metab; 2022 Jan; 17(1):83-93. PubMed ID: 34781810
[TBL] [Abstract][Full Text] [Related]
14. The effectiveness of Colchicine as an anti-inflammatory drug in the treatment of coronavirus disease 2019: Meta-analysis.
Golpour M; Mousavi T; Alimohammadi M; Mosayebian A; Shiran M; Alizadeh Navaei R; Rafiei A
Int J Immunopathol Pharmacol; 2021; 35():20587384211031763. PubMed ID: 34250834
[TBL] [Abstract][Full Text] [Related]
15. Colchicine treatment can improve outcomes of coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis.
Hariyanto TI; Halim DA; Jodhinata C; Yanto TA; Kurniawan A
Clin Exp Pharmacol Physiol; 2021 Jun; 48(6):823-830. PubMed ID: 33719081
[TBL] [Abstract][Full Text] [Related]
16. The inflammatory biomarkers profile of hospitalized patients with COVID-19 and its association with patient's outcome: A single centered study.
Hachim IY; Hachim MY; Hannawi H; Naeem KB; Salah A; Hannawi S
PLoS One; 2021; 16(12):e0260537. PubMed ID: 34855832
[TBL] [Abstract][Full Text] [Related]
17. Effect of colchicine on mortality in patients with COVID-19 - A systematic review and meta-analysis.
Zein AFMZ; Raffaello WM
Diabetes Metab Syndr; 2022 Feb; 16(2):102395. PubMed ID: 35078098
[TBL] [Abstract][Full Text] [Related]
18. Colchicine anti-inflammatory therapy for non-intensive care unit hospitalized COVID-19 patients: results from a pilot open-label, randomized controlled clinical trial.
Haroon MZ; Farooq U; Ashraf S; Zeb S; Gillani SY; Malik S; Ali R; Irshad R; Mehmood Z; Abbas Y; Masood A; Ghafoor A; Khalil AT; Asif H; Khan S; Ujjan ID; Nigar R; Livingstone S; Pascual-Figal DA; Togni S; Allergini P; Riva A; Khan A
J Physiol Pharmacol; 2022 Jun; 73(3):. PubMed ID: 36302537
[TBL] [Abstract][Full Text] [Related]
19. Basic Predictive Risk Factors for Cytokine Storms in COVID-19 Patients.
Shcherbak SG; Anisenkova AY; Mosenko SV; Glotov OS; Chernov AN; Apalko SV; Urazov SP; Garbuzov EY; Khobotnikov DN; Klitsenko OA; Minina EM; Asaulenko ZP
Front Immunol; 2021; 12():745515. PubMed ID: 34858403
[TBL] [Abstract][Full Text] [Related]
20. A double blinded placebo controlled comparative clinical trial to evaluate the effectiveness of Siddha medicines, Kaba Sura Kudineer (KSK) & Nilavembu Kudineer (NVK) along with standard Allopathy treatment in the management of symptomatic COVID 19 patients - a structured summary of a study protocol for a randomized controlled trial.
Srivastava A; Rengaraju M; Srivastava S; Narayan V; Gupta V; Upadhayay R
Trials; 2021 Feb; 22(1):130. PubMed ID: 33573696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
